677347-79-4

Usage

Uses

Used in Medicinal Chemistry:
2-(CHLOROMETHYL)-5-(PYRIDIN-3-YL)-1,3,4-OXADIAZOLE is used as a potential drug candidate for the treatment of various diseases due to its ability to interact with biological systems. Its unique structure allows for the modulation of biological pathways and targets, offering a new avenue for therapeutic intervention.
Used in Drug Development:
In the pharmaceutical industry, 2-(CHLOROMETHYL)-5-(PYRIDIN-3-YL)-1,3,4-OXADIAZOLE is utilized in the development of new drugs. Its chemical properties make it a valuable component in the design of novel therapeutic agents, potentially leading to the discovery of more effective treatments for a range of medical conditions.
Used in Agriculture:
2-(CHLOROMETHYL)-5-(PYRIDIN-3-YL)-1,3,4-OXADIAZOLE may also find applications in agriculture, where its chemical properties could be harnessed for the development of new agrochemicals or as a component in pest control strategies, contributing to more sustainable and efficient farming practices.
Used in Material Science:
In the field of material science, 2-(CHLOROMETHYL)-5-(PYRIDIN-3-YL)-1,3,4-OXADIAZOLE could be explored for its potential in creating new materials with unique properties. Its heterocyclic structure may contribute to the development of advanced materials for various applications, such as sensors, catalysts, or other specialized uses.

InChI:InChI=1/C8H6ClN3O/c9-4-7-11-12-8(13-7)6-2-1-3-10-5-6/h1-3,5H,4H2

Upstream product

• 553-53-7 Nicotinic acid hydrazide 
• 79-11-8 chloroacetic acid 
• 3250-74-6 3-(1H-tetrazol-5-yl)pyridine 
• 541-88-8 Chloroacetic anhydride 

Relevant academic research and scientific papers

Novel macrolides and ketolides having antimicrobial activity

The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-γ lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods of treating microbial infections with the compounds.

Structure-activity relationships of tyrosinase inhibitory combinatorial library of 2,5-disubstituted-1,3,4-oxadiazole analogues

Here the tyrosinase inhibition studies of library of 2,5-disubstituted-1,3, 4-oxadiazoles have been reported and their structure-activity relationship (SAR) also have been discussed. The library of the oxadiazoles was synthesized under the microwave irradiation and was structures of these were characterized by different spectral techniques. From this study it could be concluded that for a better inhibition of tyrosinase, electronegative substitution is essential as most probably the active site of the enzyme contain some hydrophobic site and position is also very important for the inhibition purposes due to the conformational space. The electronegativity of the compounds is somewhat proportional to the inhibitory activity. The compound 3e (3′-[5-(4′- bromophenyl)-1,3,4-oxadiazol-2-yl]pyridine) exhibited most potent (IC 50 = 2.18 μM) inhibition against the enzyme tyrosinase which is more potent than the standard potent inhibitor l-mimosine (IC50 = 3.68 μM). This molecule can be the best candidate as a lead compound for further development of drug for the treatments of several skin disorders.